Target intelligence / Profile preview

Argonaute 1 (AGO1)

Target
AGO1
Molecular classification
RNA-binding protein, RISC (RNA-induced silencing complex) core component, Nucleic acid-binding protein, Endonuclease (for specific subtypes such as AGO2, not clearly AGO1)
01

Overview

Argonaute 1 (AGO1) is a highly conserved RNA-binding protein and core component of the RNA-induced silencing complex (RISC), which mediates gene silencing by microRNAs (miRNAs) and, in some organisms, small interfering RNAs (siRNAs). AGO1 binds to single-stranded guide RNAs and associates with complementary sequences on target mRNAs, resulting in translational repression, mRNA deadenylation, and decay. While the best-studied endonuclease (slicing) catalytic activity among Argonaute proteins belongs to AGO2 in mammals, AGO1 functions primarily in miRNA-mediated translational inhibition. In Drosophila and plants, AGO1 is essential for normal development and cell growth regulation and may have additional roles in direct transcriptional control, such as repressing the Myc gene. Mutations in AGO1 lead to severe developmental defects, highlighting its critical function in post-transcriptional regulation. Argonaute proteins do not act as classic therapeutic targets or receptors but constitute an essential part of the RNA interference machinery fundamental to eukaryotic gene expression control.

Other names
AGO1Argonaute-1Argonaute RISC catalytic subunit 1 (human context)ARGONAUTE1AtAGO1 (in *Arabidopsis*)rde-1 (in *C. elegans*)piwi (related Drosophila family member)QDE-2 (in *Neurospora*)miRNP protein
02

Mechanism of action

Not directly targeted by drugs; molecular mechanisms include: - Formation of RISC with miRNA for translational repression or mRNA decay - Sequence-specific binding to target mRNAs via small RNA guides - In some contexts (e.g. mammals: AGO2), endonuclease ("slicer") activity

03

Biological functions

RNA interference (RNAi)MicroRNA-mediated gene silencing (miRNA pathway)Translational repressionmRNA deadenylation and decayPost-transcriptional gene regulationPotential transcriptional repression (e.g., of Myc gene in Drosophila)
04

Disease associations

Cancer (as tumor suppressor activity is described in Drosophila, especially via non-canonical regulation of Myc; human disease associations are likely, but not direct therapeutic applications)Developmental disorders (essential for normal development in model organisms; mutants have developmental defects)Other (dysregulation can impact physiological homeostasis via altered post-transcriptional regulation)
05

Safety considerations

Not applicable for direct therapeutic targeting; knockout or mutation leads to developmental lethality and neurological defects in model organisms

Beyond the preview

Go deeper on Argonaute 1 (AGO1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Argonaute 1 (AGO1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call